In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Big Year In Device Deals

Executive Summary

Given the large number of high profile deals, last year felt like a big year in the device industry, but the impression left by this handful of big and big-name deals is misleading. A chart illustrating dollar volumes in acquisitions shows a major increase in 1994, however the bulk of the value is several large consolidations—Tyco buying Kendall, for example.

You may also be interested in...

A Decade after the Fall, Device Exits Rise Again

The long era of suffering and lack of exits from medical device investments is finally over. For three straight years, public investors and strategic acquirers have shown a insatiable appetite for medical device companies with products and revenue. A panel of experts speaking at Windhover's recent audio conference Find the Right Exit: What Public Markets and Strategic Acquirers Will Offer in 2007 say the good times show no signs of ending, although risks do exist.

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts